Les Laboratoires Servier
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Les Laboratoires Servier
Amgen’s R&D programs are vitally important as sales of multiple blockbusters continue to drop, but one major late-stage asset had disappointing results and another key drug has an aggressive competitor.
Also, deals between Boehringer Ingelheim/Oxford BioTherapeutics, Bausch/Eyenovia, Ligand/HitGen, Moderna/Merck & Co., Vincera/Bayer, Genentech/Kineta, Selecta/IGAN, RedHill/AstraZeneca, Urovant/Sunovion, Biogen/Scribe, BridgeBio/Eidos, Elevar/Taiba
Analysts considered the Phase III GALACTIC-HF study of omecamtiv mecarbil a failure but some anticipated that detailed data to be presented next month could at least partially redeem the drug.
InflaRx and Relief Therapeutics/NeuroRx are investigating potential new treatments for COVID-19-induced pneumonia and for coronavirus-related ARDS.
- Generic Drugs
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- Biogaran SAS
- Egis Pharmaceuticals plc
- Servier BioInnovation
- Symphogen A/S